NextFin News - The architects of the world’s most successful medical response to the Covid-19 pandemic are stepping away from the corporate giant they built to return to the laboratory. BioNTech SE announced on Tuesday that its co-founders, Chief Executive Officer Ugur Sahin and Chief Medical Officer Özlem Türeci, will depart the company by the end of 2026 to launch a new, independent biotechnology venture focused on "next-generation" mRNA innovations. The move marks a seismic shift for the Mainz-based firm, which rose from a niche oncology specialist to a global household name and a $25 billion market heavyweight in less than five years.
Under the terms of the transition, BioNTech will contribute specific mRNA technology rights and intellectual property to the new entity in exchange for a minority equity stake, milestone payments, and future royalties. This "arm’s length" arrangement allows Sahin and Türeci to pursue high-risk, disruptive research that might otherwise be constrained by the quarterly earnings expectations and late-stage clinical focus of a publicly traded pharmaceutical major. BioNTech’s supervisory board has already initiated an executive search to replace the husband-and-wife team, whose current service agreements expire at the end of this year.
The timing of the departure is a calculated gamble. BioNTech is currently in the midst of a pivot, attempting to prove it is more than a "one-hit wonder" defined by the Comirnaty vaccine developed with Pfizer. The company has been aggressively funneling its pandemic-era cash reserves—which peaked at over €13 billion—into a late-stage pipeline of antibody-drug conjugates (ADCs) and immunomodulators. By spinning off the most experimental mRNA research into a separate vehicle led by its founders, BioNTech effectively de-risks its balance sheet for institutional investors who are increasingly hungry for predictable commercial launches rather than moonshot science.
For Sahin and Türeci, this is a return to familiar territory. The couple founded Ganymed Pharmaceuticals in 2001 before selling it to Astellas for $460 million, and then launched BioNTech in 2008 with the goal of treating cancer. The new company appears designed to bypass the "success trap" of BioNTech’s current scale. While BioNTech must now focus on the industrialization of its pipeline and the complexities of global commercialization, the new venture will likely target the fundamental limitations of current mRNA technology, such as thermal stability, targeted delivery to specific organs beyond the liver, and the "tuning" of the immune response to treat autoimmune diseases.
The market reaction reflects a mix of reverence for the founders and pragmatism about the company’s future. BioNTech shares have struggled to maintain their pandemic highs as vaccine demand cratered, and the departure of the visionary duo could be seen as a loss of the company’s "scientific soul." However, the structured nature of the split—retaining a minority stake and royalty rights—ensures that BioNTech shareholders remain tethered to whatever breakthroughs Sahin and Türeci may discover in their third act. It is a rare instance of a corporate divorce where both parties seem to agree that the laboratory is too small for the factory, and the factory is too loud for the laboratory.
Successors will inherit a company that is financially robust but strategically at a crossroads. The challenge will be maintaining the culture of rapid innovation that Sahin and Türeci instilled while managing the transition into a multi-product commercial entity. As the founders move back to the frontier of biotechnology, they leave behind a legacy that redefined the speed of modern medicine, but they also leave a vacuum that no single executive search is likely to fill entirely. The era of the founder-led BioNTech is ending, replaced by a more conventional pharmaceutical structure that must now prove it can innovate without its original creators.
Explore more exclusive insights at nextfin.ai.
